Compare TATT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TATT | TRDA |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.1M | 481.6M |
| IPO Year | 2002 | 2021 |
| Metric | TATT | TRDA |
|---|---|---|
| Price | $37.49 | $13.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $57.17 | $21.00 |
| AVG Volume (30 Days) | ★ 196.2K | 151.1K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,421,000.00 |
| Revenue This Year | $16.29 | $39.97 |
| Revenue Next Year | $16.09 | $50.80 |
| P/E Ratio | $38.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.56 | $4.93 |
| 52 Week High | $64.50 | $14.49 |
| Indicator | TATT | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 33.97 | 55.94 |
| Support Level | $34.39 | $10.84 |
| Resistance Level | $41.44 | $13.99 |
| Average True Range (ATR) | 2.45 | 0.70 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.89 | 67.23 |
TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.